Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCW9218 in Advanced Pancreatic Cancer
NCT05304936Phase 2Completed
- Sponsor
- ImmunityBio, Inc.
- Start
- Oct 2022
- Primary completion
- Feb 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of HCW9218 in pancreatic cancer (PC), sponsored by ImmunityBio, Inc.. Started Oct 2022; status: completed.
02
Drugs
HCW9218
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05304936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05304936.